Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan

被引:28
|
作者
Gelhorn, Heather L. [1 ]
Bacci, Elizabeth D. [2 ]
Poon, Jiat Ling [1 ]
Boye, Kristina S. [3 ]
Suzuki, Shuichi [4 ]
Babineaux, Steven M. [3 ]
机构
[1] Evidera, Outcomes Res, Bethesda, MD USA
[2] Evidera, Seattle, WA USA
[3] Eli Lilly & Co, Global Patient Outcomes & Real World Evidence, Indianapolis, IN 46285 USA
[4] Eli Lilly Japan, Med Dev Unit Japan, Kobe, Hyogo, Japan
来源
PATIENT PREFERENCE AND ADHERENCE | 2016年 / 10卷
关键词
discrete choice experiment; patient's preference; type; 2; diabetes; GLP-1 receptor agonists; willingness to inject; DISCRETE-CHOICE EXPERIMENT; LIRAGLUTIDE; MELLITUS;
D O I
10.2147/PPA.S109289
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The objective of this study was to use a discrete choice experiment (DCE) to estimate patients' preferences for the treatment features, safety, and efficacy of two specific glucagon-like peptide-1 receptor agonists, dulaglutide and liraglutide, among patients with type 2 diabetes mellitus (T2DM) in Japan. Methods: In Japan, patients with self-reported T2DM and naive to treatment with self-injectable medications were administered a DCE through an in-person interview. The DCE examined the following six attributes of T2DM treatment, each described by two levels: "dosing frequency", "hemoglobin A1c change", "weight change", "type of delivery system", "frequency of nausea", and "frequency of hypoglycemia". Part-worth utilities were estimated using logit models and were used to calculate the relative importance (RI) of each attribute. A chi-square test was used to determine the differences in preferences for the dulaglutide versus liraglutide profiles. Results: The final evaluable sample consisted of 182 participants (mean age: 58.9 [standard deviation = 10.0] years; 64.3% male; mean body mass index: 26.1 [standard deviation = 5.0] kg/m(2)). The RI values for the attributes in rank order were dosing frequency (44.1%), type of delivery system (26.3%), frequency of nausea (15.1%), frequency of hypoglycemia (7.4%), weight change (6.2%), and hemoglobin A1c change (1.0%). Significantly more participants preferred the dulaglutide profile (94.5%) compared to the liraglutide profile (5.5%; P<0.0001). Conclusion: This study elicited the preferences of Japanese T2DM patients for attributes and levels representing the actual characteristics of two existing glucagon-like peptide-1 receptor agonists. In this comparison, dosing frequency and type of delivery system were the two most important characteristics, accounting for >70% of the RI. These findings are similar to those of a previous UK study, providing information about patients' preferences that may be informative for patient-clinician treatment discussions.
引用
收藏
页码:1337 / 1348
页数:12
相关论文
共 50 条
  • [41] Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists
    Courtney, Hamish
    Nayar, Rahul
    Rajeswaran, Chinnadorai
    Jandhyala, Ravi
    DIABETES METABOLIC SYNDROME AND OBESITY, 2017, 10 : 79 - 87
  • [42] Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy
    Drab, Scott R.
    CURRENT DIABETES REVIEWS, 2016, 12 (04) : 403 - 413
  • [43] Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes - A systematic review and meta-analysis
    Yoshida, Yilin
    Joshi, Preeti
    Barri, Saba
    Wang, Jia
    Corder, Amy L.
    O'Connell, Samantha S.
    Fonseca, Vivian A.
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2022, 36 (08)
  • [44] Glucagon-like peptide-1 agonists: Role of the gut in hypoglycemia unawareness, and the rationale in type 1 diabetes
    Mirghani, Hyder O.
    WORLD JOURNAL OF DIABETES, 2024, 15 (11)
  • [45] Effect of glucagon-like peptide-1 receptor agonists on fat distribution in patients with type 2 diabetes: A systematic review and meta-analysis
    Duan, Kaixin
    Yan, Xiaolu
    Gao, Zhe
    Hou, Yilin
    Lv, Xiuqin
    Song, Guangyao
    JOURNAL OF DIABETES INVESTIGATION, 2022, 13 (07) : 1149 - 1160
  • [46] Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
    Bethel, M. Angelyn
    Patel, Rishi A.
    Merrill, Peter
    Lokhnygina, Yuliya
    Buse, John B.
    Mentz, Robert J.
    Pagidipati, Neha J.
    Chan, Juliana C.
    Gustavson, Stephanie M.
    Iqbal, Nayyar
    Maggioni, Aldo P.
    Ohman, Peter
    Poulter, Neil R.
    Ramachandran, Ambady
    Zinman, Bernard
    Hernandez, Adrian F.
    Holman, Rury R.
    LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (02) : 105 - 113
  • [47] Perioperative management of patients on glucagon-like peptide-1 receptor agonists
    Mizubuti, Glenio B.
    Ho, Anthony M. -H.
    da Silva, Leopoldo Muniz
    Phelan, Rachel
    CURRENT OPINION IN ANESTHESIOLOGY, 2024, 37 (03) : 323 - 333
  • [48] Cardioprotective properties of glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus patients: A systematic review
    Widiarti, Wynne
    Sukmajaya, Alverina Cynthia
    Nugraha, David
    Alkaff, Firas Farisi
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2021, 15 (03) : 837 - 843
  • [49] Glucagon-Like Peptide-1 Receptor Agonists-Use in Clinical Practice
    Trico, Domenico
    Solini, Anna
    ADVANCES IN CHRONIC KIDNEY DISEASE, 2021, 28 (04) : 328 - 336
  • [50] Adherence to NICE guidance on glucagon-like peptide-1 receptor agonists among patients with type 2 diabetes mellitus: an evaluation using the Clinical Practice Research Datalink
    Jameson, Kevin
    D'Oca, Kalpana
    Leigh, Paul
    Murray-Thomas, Tarita
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (01) : 49 - 60